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Introduction
Nowadays, new “omics” disciplines aim to shed light on post-genomic activity and/or monitor
biological functions of interest at various levels of cellular organization. Each one of these holistic
approaches exhibits its own power as well as limitations.
Pharmacogenomics focuses on individual drug variability aiming to optimize drug efficacy
and minimize toxicity (1). In the context of pharmacogenomics, though, it has been stated that
neither physiological nor environmental influences on drug pharmacokinetics are considered.
Metabolomics has been introduced to meet this exact need as metabolites provide a global inter-
pretation of biological effects (2). Metabolite identification in an individual’s body fluids is often
associated to an overall understanding of metabolic dynamics per condition of interest. As such,
metabolomic studies have a great potential toward the prediction or evaluation of drug metabolism,
permitting continued treatment with the optimal drug or dosage based on the variations in drug
metabolism and ability to respond to treatment (3, 4). The alteration in an individual’s metabolomic
profile associated with therapy (pharmacometabolomics) is expected to be one of the hallmarks of
precision medicine, as the metabotype – the metabolic profile of an individual – can assist toward a
more accurate definition of drug response and even disease heterogeneity.
In pediatrics and neonatology, drug pharmacokinetic properties differ substantially from those
in adults (in particular, during the first 4 years of a newborn’s life) (5). Hence, it is rather difficult to
obtain an effective and at the same time safe pediatric dose via a linear reduction of the adult dose.
Even today, this consists a great challenge as several drugs are not specifically approved for pediatric
use, and thus, a dosage approximation becomes necessary. Undoubtedly, there is a great potential
for metabolomic studies to rationalize therapeutic use in children (Table 1).
Applications in Neonatology
It is true that in-depth clinical research is lacking in such a vulnerable population as neonates. Thus,
the implementation of (pharmaco)metabolomics in neonatology is expected to play a key role in
order to: (i) predict the outcome of drug treatment, (ii) monitor the drug-related alterations in
metabolic pathways, and (iii) identify the metabolites (and their levels) following drug administra-
tion. Recently, both metabolomic and pharmacometabolomic studies have been focused on a range
of aspects: inborn errors of metabolism, respiratory distress syndrome, patent ductus arteriosus,
drug treatment and even maternal milk.
Patent ductus arteriosus is one of the most common congenital heart defects that preterm infants
suffer from, being associated with mutations in the germ cell line as a result of cumulated cell repli-
cations and consequently, advanced paternal age (6). Atzori et al. have employed a 1H NMR-based
metabolomic analysis of the first urine passed by term and preterm infants at early life (3–4 days)
and discriminated among the term- and preterm-infants without PDA and preterm infants with
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TABLE 1 | A synopsis of (pharmaco)metabolomics studies.
Topics Year Reference
The composition of human milk 1979 (13)
Children with autism are differentiated from their unaffected siblings and age-matched controls by urinary metabolic phenotyping 2010 (17)
Metabolomic analysis of bronchoalveolar lavage fluid in preterm infants that suffer from respiratory distress syndrome 2011 (11)
Metabolomics and Patent Ductus Arteriosus diagnosis 2011 (7)
The metabolomic profiling of children’s brains upon general anesthesia with sevoflurane and propofol. 2012 (18)
Celiac disease autoimmunity in genetically at risk infants, gluten exposure and proof of concept of microbiome–metabolome analysis 2012 (19)
The study of urinary organic acids in respiratory chain deficiencies in children 2012 (20)
persistent patent ductus arteriosus (7). Notably, the authors were
also able to define responder and non-responder phenotypes to
ibuprofen. This study implies that pharmacometabolomics may
serve as an early diagnostic and monitoring means for this defect,
avoiding unnecessary drug prophylaxis.
Respiratory distress syndrome is considered one of the impor-
tant causes of morbidity and mortality in preterm newborns, as it
is often characterized by severe complications due to endotracheal
intubation and mechanical ventilation, which leads to lung tissue
damage and surfactant inactivation (8–10). The effects of surfac-
tant therapy in preterm infants as well as their lung status were
investigated by Fabiano et al. (11). For this, serial bronchoalveolar
lavage fluid samples were collected at birth prior to surfactant
instillation, post-surfactant instillation during mechanical venti-
lation, and at extubation time-points and were analyzed by 1H
NMR spectroscopy and GC-MS (11). The analyses resulted in the
identification of 25metabolites (10 of knownmolecular structure)
that were overexpressed during mechanical ventilation, follow-
ing surfactant instillation. Metabolite identification, in this case,
could promote biomarker discovery for the respiratory distress
syndrome in preterm infants.
According to the World Health Organization guidelines,
neonates should be exclusively breast fed for the first 6months of
life (12). Human breast milk contains nutrients as well as several
bioactive components (growth factors, antimicrobial compounds,
immune-enhancing molecules) (13). However, there are claims
that breast milk alone is incapable of meeting the highly demand-
ing nutritional needs of preterm and low body weight infants (14,
15). As an alternative, formulamilk has been introduced, although
its use is still in debate. It is true that formula milk is enriched
with all the nutrients that neonates need plus iron and fatty
acids to promote brain development. Nonetheless, formulamilk is
produced according to standard recipes without considering the
inherent individuality of development that makes each preterm
infant different fromothers. A 1HNMR-basedmetabolomic study
was performed to determine the composition of breast milk from
mothers of preterm and low body weight neonates during the
first month of lactation. Significant qualitative and quantitative
differenceswere obtained,whenhumanbreastmilkwas compared
to formula milk. Notably, breast milk exhibited a great degree of
biochemical variability (16).
Applications in Childhood
Autism appears to be an excellent example. This is an early
onset developmental disorder, characterized by a severe life-long
impact on both behavior and social functioning, with associated
metabolic and gastrointestinal abnormalities whose etiology is
still unclear (5). Yap et al. investigated the urinary metabolic
phenotypes of children aged 3–9 years (39 autistic subjects, 28
non-autistic siblings, and 34 age-matched healthy subjects) using
1H NMR spectroscopy and pattern recognition methods (17).
Findings in autistic children suggested a perturbation in the
tryptophan-nicotinic acid metabolic pathway, sulfur, and amino
acid metabolism. The additional biochemical alterations found in
autistic children were consistent with some abnormalities of gut
microbiota (17). The latter could be used toward the monitoring
of therapeutic interventions.
The induction of anesthesia by either inhalation of sevoflu-
rane or intravenous propofol is common. For this, a 1H NMR
spectroscopy-based metabolomic profiling was applied to char-
acterize the cerebral metabolic status of 59 children, undergoing
NMR imaging, after approximately 60min of anesthesia (18).
Upon sevoflurane administration, higher glucose and lactate lev-
els were obtained, indicating a greater neuronal activity.
Celiac disease is a rather unique autoimmune disorder as
both genetic factors (HLA class II genes DQ2 and/or DQ8) and
environmental influences (gluten) are known to contribute, but
yet not sufficient for disease development. A thorough study
by Sellitto et al. defined (i) how the microbial communities
that colonize infants change from birth to 24months, (ii) the
impact of early vs. late gluten introduction on the gut micro-
biota and metabolome, and (iii) the switch from gluten tol-
erance to immune response (19). Notably, the microbiota of
newborns being genetically predisposed for the disease exhib-
ited great differences, when compared to those from newborns
with a non-selected genetic background. According to the retro-
spective analyses of gastrointestinal microbiota and metabolomic
findings, candidate predictive biomarkers for autoimmune devel-
opment in subjects genetically at risk might be identified. If
so, pharmaceutical interventions would be possible during the
pre-clinical phase of the disease to prevent the onset of the
disease.
A recent study investigated 39 childrenwith defined respiratory
chain deficiencies, revealing the presence of 255 endogenous and
46 exogenous substances (20). Among them, 24 metabolites were
identified, being highly and statistically significant for the com-
bined and clinically related group of respiratory chain deficien-
cies. Consequently, a metabolite profile was obtained having the
potential to define a characteristic signature for respiratory chain
deficiencies. This may enable the development of a non-invasive
screening method for respiratory chain deficiencies (20).
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Conclusion and Future Perspectives
A great potential is anticipated for metabolomics to guide ther-
apeutic choices in children, as dosage approximation is often
inevitable. We and others feel that the metabolic profile of a
pediatric patient at baseline and prior to treatment will reveal
information on individual drug response and possibly, disease
heterogeneity. This is why the holistic approach of pharma-
cometabolomics is expected to have a fundamental impact in
the future, enabling our in-depth understanding of individual
variations in drug response phenotypes as well as the design
of individualized therapeutic approaches via metabotypes’ pre-
diction. The interplay of pharmacogenomics, metabolomics, and
pharmacometabolomics is rather intriguing, as the identification
of the genetic components of the metabolome seems to be the
key, particularly during the first 4 weeks of a newborn and during
childhood. At the same time, “pharmacometabolomics-informed
pharmacogenomics” (21) is expected to give a new insight and
contribute to efforts for personalizedmedicine into pediatrics and
neonatology.
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